Tyrosine-kinase inhibitors for lung or breast cancer and drug-drug interactions: a clinical guide.

ABSTRACT:

Introduction

In the last two decades, tyrosine-kinase inhibitors (TKIs) have dramatically changed the prognosis of lung and breast cancers, with significant benefits in the metastatic setting and, more recently, in the adjuvant setting for selected groups of patients. Despite their favorable oncological effects, TKIs carry a high risk for drug-drug interactions (DDIs) due to their pharmacokinetics (PK), which depend on both pH-dependent absorption and liver metabolism. However, DDIs are frequently related to "potential DDIs" (pDDIs), and their clinical relevance is often underestimated; there is also a lack of practical guidance for clinicians.

Methods and materials

We conducted a narrative review restricted to the last 20 years, involving adult individuals (aged 18 years or

SUBMITTER: Santamaria F 

PROVIDER: S-EPMC12497703 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature